Summary.-The specificity of the tube LAI in breast cancer was examined in a study with coded samples of PBL. In addition, 64 patients with breast cancer had their LAI reactivity monitored and correlated with their clinical status for up to 3 years after mastectomy. When patients were assayed by tube LAI, 83, 72, and 29%o with Stage I, and II and III breast cancer respectively were positive. In Stage IV breast cancer, 88% of those with local recurrence and 15% of those with disseminated cancer were positive. By contrast, 3o% of control subjects were LAI+. A select group of patients admitted to hospital with suspicious breast lumps that histopathologically proved to be benign breast disease (BBD) had a higher incidence of LAI+ (12%), whereas of outpatients with BBD only 2% were LAI+. Most breast cancer patients' LAI reactivity became negative 2-4 months after mastectomy, even when some harboured micrometastases. LAI reactivity remained absent in those patients who remained clinically "cancer-free". In the follow-up patients, LAI activity returned about 4 months before local recurrence. LAI reactivity was observed in 7/8 patients in the coded study and 14/15 patients in the follow-up study preceding and/or at the time of local recurrence. A few patients (15%o,) progressed to widespread cancer without preceding positive LAI activity. The results suggest that tumour-specific immunity rapidly fades after surgery and may play no role in the rejection of micrometastases by 6 months after surgery. In addition, the present study has shown that the human host manifests tumour-specific immunity when the cancer is small, and suggests that the early detection of human cancer would depend upon reliable methods to measure the tumour-specific immune response.
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DURING the past 4 years our laboratory has assessed specific immunity to human breast cancer by the in vitro assay of tube leucocyte adherence inhibition (tube LAI) (Grosser & Thomson, 1975 Flores et al., 1977; Thomson et al., 1976) . This assay was modified from that of Holan et al. (1974) and is based on the discovery of the leucocyte adherence inhibition (LAI) phenomenon by Halliday & Miller (1972) . Many other investigators who have used LAI to study the host's immune response to animal and human tumours have reported that the assay reliably tmeasures the tumour-specific immune response of the host (Holt et al., 1975; Leveson et al., 1977; Maluish & Halliday, 1974; Powell et al., 1975; Fujisawa et al., 1977; Rutherford et al., 1977) . In contrast, Hellstrom et al. (1977) , who used the tube LAI assay in malignant melanoma, found that although the response was tumourspecific, there was too much non-specificity to be of clinical value. Also, stage of disease, amnount of clinically detectable tumour and clinical status did not influence their LAI results. Similarly, Hellstrom et al. (1976) , in an experimental animal-tumour model, found specific LAT reactivity, but great v ariation between individual tests. Likewise, Armitstead & Gowland (1975) also reported lack of specificity of an LAI assayT in colon cancer, where 590 of colonic-cancer patients and 3000 of control subjects showed LAI to a perchloric-acid extract of colonic cancer.
Our studies indicated that in cancer patients, tumour-specific immunity was generally present with small tumour burdens, and was more often absent from widespread metastasis (Grosser & Thomson, 1975 Thomson et al., 1976) . In patients with limited cancer, removal of the primary tumour was followed within 3-4 months by a loss of LAI reactivity in patienits considered to be clinically "cancer-free" Flores et al., 1977) . Leucocytes of patients with advanced cancer were not LAI+ because free breast-tumour-specific antigen (TSA) in the systemic circulation coated the cell surface of the leucocyte and abrogated the response to antigen present in the in vitro assay Lopez & Thomson, 1977) . Moreover, the breast TSA shed from the tumour-cell surface was present in serum and co-isolated with the highdensity lipoproteins and HLA antigens (Lopez & Thomson, 1977) . In addition, some of the excess TSA in the systemic circulation was degraded and cleared by glomerular filtration into the urine (Lopez & Thomson, 1977) .
In the present study, the relationship of tumour immunity to clinical behaviour of the cancer up to 3 years after mastectomy was examined in 64 patients, in an attempt to increase the understanding of the biological events of tumour growth and antitumour immunity that follow excision of the primary cancer. The present study in breast cancer and coiitrol subjects was also undertaken to determine the specificity of the tube LAI assay when leucocyte samples were coded. A further group of 41 outpatients suspected of breast pathology, who were referred for mammography, were assayed for tube LAI. Control subjects who were tested were divided into 2 groups: 92 patients with malignant tumours other than breast cancer, and 138 patients w%ith benign surgical disorders.
In the second part of the study, 64 patients who underwent mastectomy were monitored by the tube LAI every 3-6 mouths, with some patients being monitored for over 3 years. The patients studied were those who were LAI+ before surgery and wNho returned for LAI blood tests. The pathological stages of these patients at surgery was 27 Stage 1, 31 Stage II and 6 Stage 111. Most of the LAI values were correlated with the cliinical results at the end of the first, second and third year of the study. However, when a patient was LAI+ this was reported to the attending surgeon and the LAl result was then correlated with the clinical status of the patient. In this study, a single NAI value of > 30 6 months or more after surgery resulted in the patient being recorded as a positive responder. The patients were examined by their private physician or at the Oncology Clinic of the Montreal General Hospital every 3 months.
Tumour extracts.-Phosphate-buffered saline (PBS, pH 7 3) extracts of malignant melanoma and cancer of the breast, colon, stomach and pancreas were prepared as described by Grosser & Thomson (1975) . The protein concentrations were determined 661 by the method of Lowry et al. (1951) with bovine albumin as a standard, and the extracts of the specific cancer (breast) and the controls (melanoma) wN-ere titrated against peripheral blood leucocytes (PBL) from reactive breast-cancer patients and control sub)jects as previously described (Marti & Tlhomson, 1976; Flores et al., 1977) . The optimal protein concentration was about 100 + 10 Htg per tube. In the coded study conducted over a period of 1 year, the breastcancer extract was made from portions of the same breast cancer. During the 3-year follow-up study, a variety of cancer extracts, specific and non-specific, wrere prepared and used for the study. Most extracts prepared from breast cancers and malignant melanoma have had activity wAhen used in the tube LAT assay, though some extracts have seemed better than others in terms of consistent non-specific inhibition of adherence of leucocytes from control subjects. There was no discernible difference in the preparations selected for use in this study. Except for the study on the tumour specificity of the LAI response, routine testing was performed M-ith the extracts of breast cancer and malignint melanoma.
T'he antigen-induced tube leucocyte-adherencein,hibition assay (tube LAI assay). The tube LAI assay M-as performed as described in detail by Grosser & Thomson (1975) . PBL from breast-cancer patients and control subjects were collected and prepared as previously described (Grosser & Thomson, 1975 Flores et atl., 1977 Routinely, a pair of extracts was appropriately titrated for use in the tube LAI assay. The pairs of cancer extracts consisted of breast and melanoma and, more recently, colon and lung, pancreas and lung, and stomach and lung. The extract of malignant melanoma was the non-specific antigen in the coded study of LAI reactivity to breast cancer. Nevertheless, the extract of malignant melanoma showed specific antigen activity when incubated with leucocytes from patients with malignant melanoma. By studying the tumourspecific immune response to one pair of extracts, it has proved possible to maintain the experimental error (false positives) to about 3°, (O'Connor et al. in press) to one antigen of the pair. The different cancer extracts can be freely interchanged;
if, however, the number of extracts to which a patient is tested is increased, the experimental error may be expected to rise as a result of more assays being done. In addition, the percentage of patients positive to a single antigen of a panel of antigens will also rise. Although the experimental error was low, 3/6 control subjects had an LAI+ response to one of the antigens and 2/4 patients with cancer reacted falsely to an unrelated extract of cancer. It was of interest that the false positives occurred not within the standard pairs but between the pairs, in part, perhaps because the extracts of each of the pairs had not been as carefully titrated against the other pairs.
In addition, Table II shows that 92 patients with a variety of limited cancers were tested against the pair of extracts of breast cancer and melanoma with 3 positive responses (3%) to the breastcancer extract. In spite of the falsepositives recorded in Table I , the results (Table II) , but, when this patient was assayed on 2 subsequent occasions, she was LAI-, and the response to a panel of breast cancer antigens was also negative (O'Connor et al., in press).
In the control groups, 92 patients who had malignant lesions other than of the breast were assayved (Table II) Mean antigen-induced non-adherence of leucocytes from breast-cancer patients Breast cancer patients and control subjects tested during a period of about 3 months with the same specific and nonspecific tumour extracts were allocated to 3 groups (Table III) . Group 1 was control subjects with benign surgical conditions. Group 2 was LAI+ patients with localized breast cancer. Group 3 was patients with metastatic breast cancer and LAI- (Table  III) . In this analysis, the breast-cancer patients were chosen consecutively until each group had 1O patients. The group of control subjects consisted of those who were tested on the same day as the selected breast-cancer patients. Table III shows the mean leucocyte non-adherence of the 3 groups. Leucocytes from Group 1 were equally non-adherent, when incubated with the 2 cancer extracts. PBL from Group 2 incubated with the non-specific cancer extract, had a mean non-adherence similar to Group 1. By contrast, the leucocytes from Group 2 incubated with an extract of breast cancer, the sensitizing cancer, had a mean non-adherence significantly higher (P < 0-001).
Leucocytes from Group 3 showed a mean non-adherence significantly higher than Group 1, when incubated with the extracts of breast cancer and melanoma (Table III) . The mean non-adherence of leucocytes from Group 3 patients was lower, however, than in Group 2 when incubated with the extract of breast cancer. When more groups of patients were similarly examined, the results wTere the same, except that the mean nonadherence of leucocytes from Group 3 patients to the specific and non-specific antigens were almost equal to the mean non-adherence of leucocytes from Group 2 patients when incubated with the specific antigen.
Follow-utp of patients after mastectomy by the tube LAI assay
Included in this study were 64 patients who were LAI+ before surgery (Table  IV) and in 62 of these the LAI became negative 2-4 months after surgery. The patients were divided according to the month after surgery when the study was closed (Table IV) In the patients who have developed recurrences, the LAI response became positive about 4 months (range 1-7) before the local recurrence was detected. In addition, the LAI+ patients who developed local recurrence had a negative LAI value about 4 months (range 1-13) before the positive test. In the group of LAI+ patients with local recurrence, LAI reactivity was recorded about 9 months (range 4-13) before the appearance of distant metastasis.
Patterns of LAI reactivity in follow-up mastectomy patients
Figs. 1-5 show the 5 patterns of LAI reactivity observed when patienta were monitored before and after mastectomy. Fig. 1 illustrates patients progressing rapidly to the metastatic stage of cancer. Two patients were LAI+ at 6 or 7 months, and shortly after presented with clinical evidence of recurrent cancer, though as the tumour grew LAI reactivity was lost and clinical evidence of disseminated cancer followed. The third patient was LAI+ before surgery but later showed no LAI reactivity and presented within a year with evidence of disseminated breast cancer. Fig. 2 illustrates patients who to date have not developed clinically detectable recurrence of breast cancer. Invariably, these patients become LAI-2-4 months after surgery and remain negative. This does not differ from the pattern of the third patient in Fig. 1 , except that the patients in Fig. 2 have remained clinically "cancer-free". LAI-in the 2-4 months after surgery, they become LAI+ again after 6 months. Fig. 3 shows 3 LAI+ patients who are clinically "cancer-free". In Fig. 4 a similar pattern is seen, except that local recurrence of breast cancer has now become evident. Fig. 5 shows the sequence of events in patients who develop local recurrence more than 1 year after mastectomy. The LAI+ response before surgery becomes negative 2-4 months after surgery and remains negative until about 4-5 months before the local recurrence is detected clinically. The LAI response remains positive for a variable time, but the change from LAI+ to LAI-usually precedes evidence for clinical dissemination.
DISCUSSION
The validity of the in vitro microcytotoxicity assay for assessing whether human tumours do indeed express neoantigens capable of host recognition has recently been questioned (Baldwin, 1975; Herberman & Oldham, 1975) . Partly as a response to the difficulties experienced with the various methods for measuring in vitro cytotoxicity of PBL from cancer patients, attention has been directed towards developing alternative in vitro tests of cellular immunity to human tumours. The phenomenon of tumourantigen-induced inhibition of leucocyte adherence to glass (Halliday & Miller, 1972) appears to be a most promising in vitro technique. The results of the present study indicate that the assay is able to detect a host response to an organ-specific neoantigen expressed upon human cancers.
The results of the present study of tube LAI in breast-cancer patients and control subjects, in whom the PBL samples were coded and tested independently by 2 investigators, are similar to previous results from our laboratory (Grosser & Thomson, 1973; Flores et al., 1977 Lopez & Thomson, 1977) . In Stage IV cancer, the presence of LAI reactivity suggested a limited tumour load, whereas absence of a LAI response signified a large tumour load.
About 300 of control subjects had a positive LAI to the breast-cancer extract. Most of the control subjects with a false LAI+ were shown to be the result of experimental error. Thus, the experimental error in the tube LAI assay to a single antigen of the pair of extracts is about 3 o. If the number of extracts to which the patients are tested is increased, the rate of false positives may rise. With 6 different cancer antigens and the use of our formula, there are 30 permutations by which the NAI can be calculated for the nonadherent PBL from one subject incubated with the 6 antigens. An experimental error rate of 2.5% will lead to more than 5000 of tested control subjects being apparently positive once in the 30 possible permutations of the 6 antigens. By contrast, PBL from a tumour-bearing patient with tumour-specific immunity can be expected to be positive to the sensitizing antigen in 5/5 possible combinations in which the sensitizing antigen is the specific antigen, out of the 30 different permutations for calculating the NAI, a result which is markedly different from the control subjects. Nevertheless, in the present state of development of the tube LAI, the use of a panel of cancer extracts has little applicability as a cancer-screening (Haywood & McKhann, 1971; Black et al., 1976; Deichman & Kluchareva, 1966; Fenyo et al., 1968 The presence of LAI reactivity some months before the tumour is detectable suggests that 105-106 tumour cells may be required to stimulate the LAI response. Another possible explanation of the disappearance of antitumour immunity in patients after surgery who harbour micrometastases is that the cancer cells are in an immunologically privileged location.
The LAI results of the monitored patients suggests that the antitumour immunity of the host fades, and that the tumour-specific immune response ceases to play an active role in the rejection of micrometastases by 6 months after surgery. Not until the micrometastases have increased in cell numbers does the immune system return. Of course, other aspects of the tumour-specific immune response, not measured by tube LAI, could be active, and their failure may allow the tumour to escape and enter a rapid growth phase. Assessment of other aspects of the immune response to tumours by in vitro assays of microcytotoxicity, cytotoxicity and macrophage migration in human tumours have also detected, however, the waning of antitumour immunity after surgery (Anderson et al., 1970; Bull et al., 1973; Jones & Turnbull, 1974; Reiche et al., 1976; Elias et al., 1977; Canevari et al., 1975; O'Toole et al., 1973;  Unsgaard & O'Toole, 1975) .
In an animal model, Eccles & Alexander (1972) showed that the antitumour immune response expressed in the first month after surgery is critical in determining whether micrometastases are rejected or eventually grow. In human cancer the extent and duration of the transient immunosuppression produced by surgery (Grosser & Thomson, 1975; and the vigour of the antitumour immune response in the month or so immediately after surgery, may prove to be critical factors that determine the fate of micrometastases.
In aIn animal tumour model, the host's tumour-specific immune response was detectable before TSA could be measured in the circulation (Thomson, 1975) . Serological tests for the detection of tumour products in human sera, such as carcinoembryonic antigen (Thomson et al., 1969) and alkaline phosphatase (Foti et al., 1977) , give the greatest values when the tumour burden is comparatively large. The present study suggests that the human host also expresses tumour-specific immunity when the tumour burden is small; thus, the early detection of human cancer by immunological assays will depend on the development of reliable methods to measure the antitumour immune response.
